D. Baumgart and W. Sandborn, Inflammatory bowel disease: clinical aspects and established and evolving therapies, The Lancet, vol.369, issue.9573, pp.1641-57, 2007.
DOI : 10.1016/S0140-6736(07)60751-X

E. Loftus and J. , Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, Gastroenterology, vol.126, issue.6, pp.1504-1521, 2004.
DOI : 10.1053/j.gastro.2004.01.063

J. Cho, The genetics and immunopathogenesis of inflammatory bowel disease, Nature Reviews Immunology, vol.316, issue.6, pp.458-66, 2008.
DOI : 10.1038/nri2340

C. Tamboli, C. Neut, P. Desreumaux, and J. Colombel, Dysbiosis as a prerequisite for IBD, Gut, vol.53, pp.1057-1062, 2004.

J. Gratadoux, Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients, Proc Natl Acad Sci U S A, vol.105, pp.16731-16737, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00652961

C. Moehle, N. Ackermann, T. Langmann, C. Aslanidis, A. Kel et al., Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease, Journal of Molecular Medicine, vol.99, issue.Pt 3, pp.1055-66, 2006.
DOI : 10.1007/s00109-006-0100-2

K. Hill, K. Wang, S. Stryker, R. Gupta, D. Weinrach et al., Comparative analysis of cell adhesion molecules, cell cycle regulatory proteins, mismatch repair genes, cyclooxygenase-2, and DPC4 in carcinomas arising in inflammatory bowel disease and sporadic colon cancer, Oncology Reports, vol.11, pp.951-957, 2004.
DOI : 10.3892/or.11.5.951

M. Ramasundara, S. Leach, D. Lemberg, and A. Day, Defensins and inflammation: The role of defensins in inflammatory bowel disease, Journal of Gastroenterology and Hepatology, vol.56, issue.2, pp.202-210, 2009.
DOI : 10.1111/j.1440-1746.2008.05772.x

A. Smith, F. Rahman, B. Hayee, S. Graham, D. Marks et al., Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease, The Journal of Experimental Medicine, vol.35, issue.9, pp.1883-97, 2009.
DOI : 10.1038/nature06005
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737162

D. Baumgart and S. Carding, Inflammatory bowel disease: cause and immunobiology, The Lancet, vol.369, issue.9573, pp.1627-1667, 2007.
DOI : 10.1016/S0140-6736(07)60750-8

A. Hart, H. Hassi, R. Rigby, S. Bell, A. Emmanuel et al., Characteristics of Intestinal Dendritic Cells in Inflammatory Bowel Diseases, Gastroenterology, vol.129, issue.1, pp.50-65, 2005.
DOI : 10.1053/j.gastro.2005.05.013

E. Cario and D. Podolsky, Differential Alteration in Intestinal Epithelial Cell Expression of Toll-Like Receptor 3 (TLR3) and TLR4 in Inflammatory Bowel Disease, Infection and Immunity, vol.68, issue.12, pp.7010-7017, 2000.
DOI : 10.1128/IAI.68.12.7010-7017.2000

S. Maeda, L. Hsu, H. Liu, L. Bankston, M. Iimura et al., Nod2 Mutation in Crohn's Disease Potentiates NF-??B Activity and IL-1?? Processing, Science, vol.307, issue.5710, pp.734-742, 2005.
DOI : 10.1126/science.1103685

T. Watanabe, A. Kitani, P. Murray, and W. Strober, NOD2 is a negative regulator of Toll-like receptor 2???mediated T helper type 1 responses, Nature Immunology, vol.52, issue.8, pp.800-808, 2004.
DOI : 10.1016/S0006-291X(02)02807-3

N. Inohara, Y. Ogura, A. Fontalba, O. Gutierrez, F. Pons et al., Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2: IMPLICATIONS FOR CROHN'S DISEASE, Journal of Biological Chemistry, vol.278, issue.8, pp.5509-5521, 2003.
DOI : 10.1074/jbc.C200673200

G. Bamias, K. Sugawara, C. Pagnini, and F. Cominelli, The Th1 immune pathway as a therapeutic target in Crohn's disease, Curr Opin Investig Drugs, vol.4, pp.1279-86, 2003.

S. Targan and L. Karp, Defects in mucosal immunity leading to ulcerative colitis, Immunological Reviews, vol.95, issue.1, pp.296-305, 2005.
DOI : 10.1016/S0016-5085(03)00271-3

S. Fujino, A. Andoh, S. Bamba, A. Ogawa, K. Hata et al., Increased expression of interleukin 17 in inflammatory bowel disease, Gut, vol.52, issue.1, pp.65-70, 2003.
DOI : 10.1136/gut.52.1.65

S. Leung-theung-long and S. Guerder, Les cellules Th17, m??decine/sciences, vol.24, issue.11, pp.972-978, 2008.
DOI : 10.1051/medsci/20082411972

L. Peyrin-biroulet, E. Parmentier-decrucq, J. Branche, and P. Desreumaux, , un nouveau g??ne de susceptibilit?? dans les maladies inflammatoires chroniques intestinales, m??decine/sciences, vol.23, issue.3, pp.250-252, 2007.
DOI : 10.1051/medsci/2007233250

G. Matsuzaki and M. Umemura, Interleukin-17 as an Effector Molecule of Innate and Acquired Immunity against Infections, Microbiology and Immunology, vol.109, issue.12, pp.1139-1186, 2007.
DOI : 10.1111/j.1348-0421.2007.tb04008.x

E. Bettelli, Y. Carrier, W. Gao, T. Korn, T. Strom et al., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease, Nature Eur J Pharmacol Gut, vol.44158552, pp.235-8361, 2003.

N. Zimmerman, R. Vongsa, M. Wendt, and M. Dwinell, Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease, Inflammatory Bowel Diseases, vol.14, issue.7, pp.1000-1011, 2008.
DOI : 10.1002/ibd.20480

I. Koutroubakis, G. Tsiolakidou, K. Karmiris, and E. Kouroumalis, Role of angiogenesis in inflammatory bowel disease, Inflammatory Bowel Diseases, vol.12, issue.6, pp.515-538, 2006.
DOI : 10.1097/00054725-200606000-00012

R. Adams, S. Heazlewood, K. Gilshenan, O. Brien, M. Mcguckin et al., IgG Antibodies Against Common Gut Bacteria Are More Diagnostic for Crohn's Disease Than IgG Against Mannan or Flagellin, The American Journal of Gastroenterology, vol.102, issue.8, pp.386-96, 2008.
DOI : 10.1189/jlb.0805484